6meg - Revision history

OCA at 06:29, 11 October 2023

2023-10-11T06:29:59Z

←Older revision		Revision as of 06:29, 11 October 2023
Line 3:		Line 3:
	<StructureSection load='6meg' size='340' side='right'caption='[[6meg]], [[Resolution\|resolution]] 1.41Å' scene=''>		<StructureSection load='6meg' size='340' side='right'caption='[[6meg]], [[Resolution\|resolution]] 1.41Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6meg]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEG OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6MEG FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6meg]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6MEG FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6meg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6meg OCA], [~~http~~://pdbe.org/6meg PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6meg RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6meg PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6meg ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.41Å</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6meg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6meg OCA], [https://pdbe.org/6meg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6meg RCSB], [https://www.ebi.ac.uk/pdbsum/6meg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6meg ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 17:		Line 18:

	==See Also==		==See Also==
-	*[[~~Antibody~~ 3D structures\|~~Antibody~~ 3D structures]]	+	*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]
		+	*[[Sandbox 20009\|Sandbox 20009]]
		+	*[[3D structures of human antibody\|3D structures of human antibody]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Bjorkman~~, P J~~]]	+	[[Category: Bjorkman PJ]]
-	[[Category: Flyak~~, A I]]~~	+	[[Category: Flyak AI]]
-	~~[[Category: Broadly neutralizing antibody]]~~	+
-	~~[[Category: Hcv glycoprotein]]~~	+
-	~~[[Category: Immune system~~]]	+

OCA at 08:24, 6 November 2019

2019-11-06T08:24:09Z

←Older revision		Revision as of 08:24, 6 November 2019
Line 1:		Line 1:

-	==~~Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design~~==	+	==Crystal structure of human monoclonal antibody HEPC46==
-	<StructureSection load='6meg' size='340' side='right' caption='[[6meg]], [[Resolution\|resolution]] 1.41Å' scene=''>	+	<StructureSection load='6meg' size='340' side='right'caption='[[6meg]], [[Resolution\|resolution]] 1.41Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[6meg]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MEG FirstGlance]. <br>		<table><tr><td colspan='2'>[[6meg]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MEG FirstGlance]. <br>
Line 15:		Line 15:
	</div>		</div>
	<div class="pdbe-citations 6meg" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6meg" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 20:		Line 23:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Bjorkman, P J]]		[[Category: Bjorkman, P J]]
	[[Category: Flyak, A I]]		[[Category: Flyak, A I]]

OCA at 21:09, 2 December 2018

2018-12-02T21:09:37Z

←Older revision		Revision as of 21:09, 2 December 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6meg is ~~ON HOLD until Paper~~ Publication	+	==Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design==
		+	<StructureSection load='6meg' size='340' side='right' caption='[[6meg]], [[Resolution\|resolution]] 1.41Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[6meg]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MEG FirstGlance]. <br>
		+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6meg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6meg OCA], [http://pdbe.org/6meg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6meg RCSB], [http://www.ebi.ac.uk/pdbsum/6meg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6meg ProSAT]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Hepatitis C virus (HCV) vaccine efforts are hampered by the extensive genetic diversity of HCV envelope glycoproteins E1 and E2. Structures of broadly neutralizing antibodies (bNAbs) (e.g., HEPC3, HEPC74) isolated from individuals who spontaneously cleared HCV infection facilitate immunogen design to elicit antibodies against multiple HCV variants. However, challenges in expressing HCV glycoproteins previously limited bNAb-HCV structures to complexes with truncated E2 cores. Here we describe crystal structures of full-length E2 ectodomain complexes with HEPC3 and HEPC74, revealing lock-and-key antibody-antigen interactions, E2 regions (including a target of immunogen design) that were truncated or disordered in E2 cores, and an antibody CDRH3 disulfide motif that exhibits common interactions with a conserved epitope despite different bNAb-E2 binding orientations. The structures display unusual features relevant to common genetic signatures of HCV bNAbs and demonstrate extraordinary plasticity in antibody-antigen interactions. In addition, E2 variants that bind HEPC3/HEPC74-like germline precursors may represent candidate vaccine immunogens.

-	~~Authors:~~ Flyak, ~~A.I.~~, ~~Bjorkman~~, P.J.	+	HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.,Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE Jr, Bailey JR, Bjorkman PJ Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3. doi: 10.1016/j.chom.2018.10.009. PMID:30439340<ref>PMID:30439340</ref>

-	~~Description: Broadly neutralizing antibodies against HCV use~~ a ~~CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
-	[[Category: Bjorkman, P.J]]	+	<div class="pdbe-citations 6meg" style="background-color:#fffaf0;"></div>
-	[[Category: Flyak, A.I]]	+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Bjorkman, P J]]
		+	[[Category: Flyak, A I]]
		+	[[Category: Broadly neutralizing antibody]]
		+	[[Category: Hcv glycoprotein]]
		+	[[Category: Immune system]]

OCA at 06:27, 26 September 2018

2018-09-26T06:27:39Z

←Older revision		Revision as of 06:27, 26 September 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6meg is ON HOLD	+	The entry 6meg is ON HOLD until Paper Publication

	Authors: Flyak, A.I., Bjorkman, P.J.		Authors: Flyak, A.I., Bjorkman, P.J.

OCA: Protected "6meg" [edit=sysop:move=sysop]

2018-09-12T06:18:44Z

Protected "6meg" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:18, 12 September 2018

OCA: New page: '''Unreleased structure''' The entry 6meg is ON HOLD Authors: Flyak, A.I., Bjorkman, P.J. Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recogn...

2018-09-12T06:18:43Z

New page: '''Unreleased structure''' The entry 6meg is ON HOLD Authors: Flyak, A.I., Bjorkman, P.J. Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recogn...

New page

'''Unreleased structure'''

The entry 6meg is ON HOLD

Authors: Flyak, A.I., Bjorkman, P.J.

Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design
[[Category: Unreleased Structures]]
[[Category: Bjorkman, P.J]]
[[Category: Flyak, A.I]]